Latest Articles

Article prepared by and republished courtesy of our colleagues Christine Daya, Thomas M DeButts, Danish Hamid, Sarah E. Kahn, Richard Newcomb, Ignacio E. Sanchez, Lawrence E. Levinson and Dana Zelman; originally published here: https://www.dlapiper.com/en/us/insights/publications/2020/01/new-regulations-reinforce-cfius-expanded-role/. On January 13, 2020, the US Department of the Treasury released two sets of new regulations that comprehensively implement the Foreign Investment Risk Review Modernization Act (FIRRMA) – a law that strengthens the…
The US Department of Transportation and the White House have released a new federal government automated vehicle policy guide, “Ensuring American Leadership in Automated Vehicle Technologies: Automated Vehicles 4.0.” The report describes research, policy, funding and other efforts by 38 different federal government agencies in support of the development and deployment of automated vehicles in the United States. While it primarily focuses on providing general descriptions of the activities of agencies that have responsibility for…
Effective January 6, the US Department of Commerce, Bureau of Industry and Security (BIS) has imposed new export controls on geospatial imagery software that is used in areas including self-driving vehicles, drone navigation, remote sensing, and analysis of earth imagery. The new export control requires that an export license be obtained for software specially designed to automate the analysis of certain geospatial imagery. Companies that export this software should immediately take action to comply with…
In the latest issue of AI Outlook − a new DLA Piper publication that reports on the latest developments around artificial intelligence in Washington − we discuss the Trump Administration’s long-awaited guidelines governing how federal agencies should develop and use artificial intelligence (AI) technologies. The memorandum names a number of top priorities, including fairness and non-discrimination, transparency, flexibility, public trust and participation, sound science, and safety and security, as agencies draft and implement regulations on…
Article prepared by and republished courtesy of our colleagues Larry W. Nishnick, Bradley E. Phipps, and David Kurlander; originally published here: https://www.dlapiper.com/en/asiapacific/insights/publications/2020/01/sec-proposes-changes-to-accredited-investor-definition/. The SEC recently proposed amendments to the long-standing definition of “accredited investor,” an important qualification standard under the securities laws that determines what types of investors may invest in certain kinds of private securities offerings, including securities offerings conducted pursuant to Rules 506(b) and 506(c) of Regulation D under…
On December 19, the National Institute of Standards and Technology (NIST), a federal agency within the Department of Commerce, released a study on demographic differentials for contemporary face recognition algorithms. The study describes and quantifies demographic differentials for contemporary face recognition algorithms. Essentially, the purpose of the study was to measure how accurately face recognition software tools identify people of varied sex, age and racial background. The results of the report are intended to inform policymakers and…
This issue of AI Outlook − a new DLA Piper publication that reports on the latest developments around artificial intelligence in Washington − we discuss next week’s House Oversight and Investigations Committee hearing, which will look into the national security implications of facial recognition technology. The hearing, tentatively set for the week of December 16, is the latest demonstration of Congressional interest in facial recognition technology and its public policy implications. Learn more in the
Developments in technology are driving major change across all sectors and, in many cases, these changes are significantly impacting legal developments in a particular industry. In the past, pharmaceutical and medical device product liability litigations typically commenced following major regulatory action by the US Food and Drug Administration, such as a label change or a product withdrawal. However, the increasing accessibility of real-world data, social media and post-marketing adverse event reporting has flipped the script:…